Nov 30

HC Roundtable: Technological developments in the IVD world

Third Healthcare Roundtable of the AHK Japan

Topic: Technological developments in the IVD world
Speakers:
Dr. Andreas F. Stange, Vice President MHS global IVD, TÜV SÜD Japan Ltd.
Mr. Tsujimoto Kenji, Executive Vice President, Technology Strategy at Sysmex Corporation
Time & Date: November 30 (Fri.) 2018, 16:45 – 19:00
Location: Draeger Japan Ltd.

About the Event

As of 2017, over 30 German companies are active in the industries of Healthcare & Medical Devices in Japan and this new roundtable gives representatives not only the latest and most accurate insider news, it also allows participants to engage in a dialogue with experts and industry peers on a regular basis.

Participation is free of charge and open to all industry representatives that are providing health care services and products.

The IVD field is undergoing rapid technological developments that have a profound effect on everybody’s live. In our event, we want to discuss the technology developments as well the changes of the regulatory and reimbursement landscape in EU and East Asia.

==================
Session 1:
Technological developments in the IVD world that effect all our lives
==================

Speaker:
Dr. Andreas F. Stange
Vice President MHS global IVD, TÜV SÜD Japan Ltd.

-------------------------

Introduction to the rapid technological developments in in-vitro-diagnostic field.

==================
Session 2:
IVD is Key for Precision Medicine
==================

Speaker:
Mr. Tsujimoto Kenji
Executive Vice President, Technology Strategy at Sysmex Corporation
-------------------------

The importance of the precision medicine is dramatically growing. Since the release of the guideline from FDA, a number of companion diagnostics (CDx), which can guide therapy selection, have been approved globally.

Furthermore, one of the latest progress is the fact that NGS (next generation sequencing)-based assay is moving into the clinical space from research. For example, the Japanese government takes an initiative to realize “genomic medicine” for, but not limited to, patients with cancer.

We will see more progress in the future, including digital medicine. In this session, the dynamics of precision medicine, now and future, will be presented as well as contributions of in vitro diagnostics (IVD) with some examples of Sysmex R&D.

Zurück zur Liste